Literature DB >> 31270150

Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor.

Caroline S Gravastrand1,2, Bjørg Steinkjer1,2, Bente Halvorsen3,4,5, Anne Landsem6,7, Mona Skjelland8, Eva Astrid Jacobsen9, Trent M Woodruff10, John D Lambris11, Tom E Mollnes1,6,7,12, Ole-Lars Brekke6,7, Terje Espevik1,2, Anne Mari A Rokstad13,2,14.   

Abstract

Cholesterol crystals (CC) are strong activators of complement and could potentially be involved in thromboinflammation through complement-coagulation cross-talk. To explore the coagulation-inducing potential of CC, we performed studies in lepirudin-based human whole blood and plasma models. In addition, immunohistological examinations of brain thrombi and vulnerable plaque material from patients with advanced carotid atherosclerosis were performed using polarization filter reflected light microscopy to identify CC. In whole blood, CC exposure induced a time- and concentration-dependent generation of prothrombin fragment 1+2 (PTF1.2), tissue factor (TF) mRNA synthesis, and monocyte TF expression. Blocking Abs against TF abolished CC-mediated coagulation, thus indicating involvement of the TF-dependent pathway. Blockade of FXII by corn trypsin inhibitor had a significant inhibitory effect on CC-induced PTF1.2 in platelet-free plasma, although the overall activation potential was low. CC exposure did not induce platelet aggregation, TF microparticle induction, or TF on granulocytes or eosinophils. Inhibition of complement C3 by CP40 (compstatin), C5 by eculizumab, or C5aR1 by PMX53 blocked CC-induced PTF1.2 by 90% and reduced TF+ monocytes from 18-20 to 1-2%. The physiologic relevance was supported by birefringent CC structures adjacent to monocytes (CD14), TF, and activated complement iC3b and C5b-9 in a human brain thrombus. Furthermore, monocyte influx and TF induction in close proximity to CC-rich regions with activated complement were found in a vulnerable plaque. In conclusion, CC could be active, releasable contributors to thrombosis by inducing monocyte TF secondary to complement C5aR1 signaling.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Year:  2019        PMID: 31270150      PMCID: PMC6680065          DOI: 10.4049/jimmunol.1900503

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Tissue factor in neutrophils: yes.

Authors:  S Nakamura; T Imamura; K Okamoto
Journal:  J Thromb Haemost       Date:  2004-02       Impact factor: 5.824

2.  Tissue factor in neutrophils: no.

Authors:  B Østerud
Journal:  J Thromb Haemost       Date:  2004-02       Impact factor: 5.824

3.  Importance of C-reactive protein in regulating monocyte tissue factor expression in patients with inflammatory rheumatic diseases.

Authors:  Hong Cai; Changjie Song; Irwin Geok San Lim; Steven A Krilis; Carolyn L Geczy; H Patrick McNeil
Journal:  J Rheumatol       Date:  2005-07       Impact factor: 4.666

4.  Generation of C-reactive protein and complement components in atherosclerotic plaques.

Authors:  K Yasojima; C Schwab; E G McGeer; P L McGeer
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

5.  A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways.

Authors:  Konstantinos Ritis; Michael Doumas; Dimitrios Mastellos; Anastasia Micheli; Stavros Giaglis; Paola Magotti; Stavros Rafail; Georgios Kartalis; Paschalis Sideras; John D Lambris
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

6.  Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques.

Authors:  K Yasojima; C Schwab; E G McGeer; P L McGeer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-07       Impact factor: 8.311

Review 7.  Platelets and tissue factor.

Authors:  W Lösche
Journal:  Platelets       Date:  2005-09       Impact factor: 3.862

8.  Oxidized LDL in carotid plaques and plasma associates with plaque instability.

Authors:  Kyoko Nishi; Hiroyuki Itabe; Masaaki Uno; Keiko T Kitazato; Hidehisa Horiguchi; Kiyohito Shinno; Shinji Nagahiro
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-10-01       Impact factor: 8.311

9.  Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation.

Authors:  Tom Eirik Mollnes; Ole-Lars Brekke; Michael Fung; Hilde Fure; Dorte Christiansen; Grethe Bergseth; Vibeke Videm; Knut Tore Lappegård; Jörg Köhl; John D Lambris
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

10.  Platelet activation leads to activation and propagation of the complement system.

Authors:  Ian Del Conde; Miguel A Crúz; Hui Zhang; José A López; Vahid Afshar-Kharghan
Journal:  J Exp Med       Date:  2005-03-21       Impact factor: 14.307

View more
  9 in total

Review 1.  Complementopathies and precision medicine.

Authors:  Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 2.  COVID-19: Complement, Coagulation, and Collateral Damage.

Authors:  Martin W Lo; Claudia Kemper; Trent M Woodruff
Journal:  J Immunol       Date:  2020-07-22       Impact factor: 5.422

3.  Factor H-related protein 1 (FHR-1) is associated with atherosclerotic cardiovascular disease.

Authors:  Sarah Irmscher; Svante L H Zipfel; Luke D Halder; Lia Ivanov; Andres Gonzalez-Delgado; Christoph Waldeyer; Moritz Seiffert; Fabian J Brunner; Monika von der Heide; Ina Löschmann; Sonia Wulf; Darina Czamara; Nikolina Papac-Milicevic; Olaf Strauß; Stefan Lorkowski; Hermann Reichenspurner; Michael V Holers; Nirmal K Banda; Tania Zeller; Elisabeth B Binder; Christoph J Binder; Thorsten Wiech; Peter F Zipfel; Christine Skerka
Journal:  Sci Rep       Date:  2021-11-18       Impact factor: 4.379

Review 4.  Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19.

Authors:  Danielle Brain; Alex Plant-Hately; Bethany Heaton; Usman Arshad; Christopher David; Christian Hedrich; Andrew Owen; Neill J Liptrott
Journal:  Adv Drug Deliv Rev       Date:  2021-06-25       Impact factor: 17.873

5.  Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis.

Authors:  Nathalie Niyonzima; Siril S Bakke; Ida Gregersen; Sverre Holm; Øystein Sandanger; Hilde L Orrem; Bjørnar Sporsheim; Liv Ryan; Xiang Yi Kong; Tuva Børresdatter Dahl; Mona Skjelland; Kirsten Krohg Sørensen; Anne Mari Rokstad; Arne Yndestad; Eicke Latz; Lars Gullestad; Geir Ø Andersen; Jan Kristian Damås; Pål Aukrust; Tom E Mollnes; Bente Halvorsen; Terje Espevik
Journal:  EBioMedicine       Date:  2020-09-11       Impact factor: 8.143

6.  Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages.

Authors:  Claudia Donat; Sophia Thanei; Marten Trendelenburg
Journal:  Front Immunol       Date:  2019-11-21       Impact factor: 7.561

7.  Cholesterol Crystals and NLRP3 Mediated Inflammation in the Uterine Wall Decidua in Normal and Preeclamptic Pregnancies.

Authors:  Gabriela Brettas Silva; Lobke Marijn Gierman; Johanne Johnsen Rakner; Guro Sannerud Stødle; Siv Boon Mundal; Astrid Josefin Thaning; Bjørnar Sporsheim; Mattijs Elschot; Karin Collett; Line Bjørge; Marie Hjelmseth Aune; Liv Cecilie Vestrheim Thomsen; Ann-Charlotte Iversen
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

8.  C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake Naja annulifera.

Authors:  Felipe Silva de França; Isadora Maria Villas-Boas; Bruno Cogliati; Trent M Woodruff; Edimara da Silva Reis; John D Lambris; Denise V Tambourgi
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

Review 9.  Mechanisms of SARS-CoV-2-induced lung vascular disease: potential role of complement.

Authors:  Kurt R Stenmark; Maria G Frid; Evgenia Gerasimovskaya; Hui Zhang; Mary K McCarthy; Joshua M Thurman; Thomas E Morrison
Journal:  Pulm Circ       Date:  2021-05-18       Impact factor: 3.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.